Literature DB >> 18515255

SERPINA1 gene variants in individuals from the general population with reduced alpha1-antitrypsin concentrations.

Michele Zorzetto1, Erich Russi, Oliver Senn, Medea Imboden, Ilaria Ferrarotti, Carmine Tinelli, Ilaria Campo, Stefania Ottaviani, Roberta Scabini, Arnold von Eckardstein, Wolfgang Berger, Otto Brändli, Thierry Rochat, Maurizio Luisetti, Nicole Probst-Hensch.   

Abstract

BACKGROUND: Individuals with severe deficiency in serum alpha(1)-antitrypsin (AAT) concentrations are at high risk for developing chronic obstructive pulmonary disease (COPD), whereas those carrying the PI*MZ genotype are at slightly increased risk. Testing appropriate subgroups of the population for AAT deficiency (AATD) is therefore an important aspect of COPD prevention and timely treatment. We decided to perform an exhaustive investigation of SERPINA1 gene variants in individuals from the general population with a moderately reduced serum AAT concentration, because such information is currently unavailable.
METHODS: We determined the Z and S alleles of 1399 individuals enrolled in the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA) with serum AAT concentrations < or = 1.13 g/L and submitted 423 of these samples for complete exon 2-->5 sequencing.
RESULTS: We found that 900 of 1399 samples (64%), carried the normal PI*MM genotype, whereas 499 samples (36%) carried at least 1 SERPINA1 deficiency variant. In the subpopulations in which AAT concentrations ranged from > 1.03 to < or = 1.13 and from > 0.93 to < or = 1.03 g/L, individuals with the PI*MM genotype represented the majority (86.5% and 53.8%, respectively). The PI*MS genotype was predominant (54.9%) in the AAT range of 0.83 to 0.93 g/L, whereas PI*MZ represented 76.4% in the AAT range of > 0.73 to < or = 0.83 g/L.
CONCLUSIONS: This analysis provided a detailed molecular definition of intermediate AATD, which would be helpful in the diagnostic setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18515255     DOI: 10.1373/clinchem.2007.102798

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  23 in total

1.  A novel alpha1-antitrypsin null variant (PiQ0Milano ).

Authors:  Raffaela Rametta; Gabriella Nebbia; Paola Dongiovanni; Marcello Farallo; Silvia Fargion; Luca Valenti
Journal:  World J Hepatol       Date:  2013-08-27

2.  Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.

Authors:  Darcy D Marciniuk; P Hernandez; M Balter; J Bourbeau; K R Chapman; G T Ford; J L Lauzon; F Maltais; D E O'Donnell; D Goodridge; C Strange; A J Cave; K Curren; S Muthuri
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

Review 3.  Airway hydration and COPD.

Authors:  Arunava Ghosh; R C Boucher; Robert Tarran
Journal:  Cell Mol Life Sci       Date:  2015-06-12       Impact factor: 9.261

4.  Alpha 1 antitrypsin deficiency alleles are associated with joint dislocation and scoliosis in Williams syndrome.

Authors:  Colleen A Morris; Ariel M Pani; Carolyn B Mervis; Cecilia M Rios; Doris J Kistler; Ronald G Gregg
Journal:  Am J Med Genet C Semin Med Genet       Date:  2010-05-15       Impact factor: 3.908

5.  Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?

Authors:  Dawn McGee; Laura Schwarz; Rebecca McClure; Lauren Peterka; Farshid Rouhani; Mark Brantly; Charlie Strange
Journal:  Pulm Med       Date:  2010-06-28

Review 6.  Challenges and Prospects for Alpha-1 Antitrypsin Deficiency Gene Therapy.

Authors:  Joanna Wozniak; Tomasz Wandtke; Piotr Kopinski; Joanna Chorostowska-Wynimko
Journal:  Hum Gene Ther       Date:  2015-09-29       Impact factor: 5.695

7.  Behavioral impact of return of genetic test results for complex disease: Systematic review and meta-analysis.

Authors:  Maia J Frieser; Sylia Wilson; Scott Vrieze
Journal:  Health Psychol       Date:  2018-10-11       Impact factor: 4.267

8.  Three new alpha1-antitrypsin deficiency variants help to define a C-terminal region regulating conformational change and polymerization.

Authors:  Anna M Fra; Bibek Gooptu; Ilaria Ferrarotti; Elena Miranda; Roberta Scabini; Riccardo Ronzoni; Federica Benini; Luciano Corda; Daniela Medicina; Maurizio Luisetti; Luisa Schiaffonati
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

9.  Screening for Alpha 1 antitrypsin deficiency in Tunisian subjects with obstructive lung disease: a feasibility report.

Authors:  Sabri Denden; Michele Zorzetto; Fethi Amri; Jalel Knani; Stefania Ottaviani; Roberta Scabini; Marina Gorrini; Ilaria Ferrarotti; Ilaria Campo; Jemni Ben Chibani; Amel Haj Khelil; Maurizio Luisetti
Journal:  Orphanet J Rare Dis       Date:  2009-04-15       Impact factor: 4.123

10.  SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort.

Authors:  Gian-Andri Thun; Ilaria Ferrarotti; Medea Imboden; Thierry Rochat; Margaret Gerbase; Florian Kronenberg; Pierre-Olivier Bridevaux; Elisabeth Zemp; Michele Zorzetto; Stefania Ottaviani; Erich W Russi; Maurizio Luisetti; Nicole M Probst-Hensch
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.